Abstract
Multiple sclerosis (MS) is a demyelinating disease of the central nervous system of unknown etiology. Two of the major therapies for the treatment of MS, interferon-β and glatiramer acetate, show only limited evidence that long-term treatment slows disability. There is a great need for new drugs that will halt, reverse, and prevent the development of MS. This article reviews therapies currently in use and describes innovative strategies being developed to alter the disease course. New technologies in gene expression profiling offer hopeful directions toward the design of successful drug therapies and diagnostic testing for MS. Additionally, the new fields of genomics and proteomics offer the promise of novel treatments, and should help to reveal the mechanisms of disease initiation and pathological progression.
Keywords: Multiple Sclerosis, demyelinating disease, Demyelination, Autoimmune, Glatiramer Acetate, Immunomodulators, Mitoxantrone, Gene Therapy, Microarrays, BIOMARKERS
Current Drug Targets - CNS & Neurological Disorders
Title: Multiple Sclerosis: Emerging Opportunities for Therapeutic Intervention
Volume: 1 Issue: 1
Author(s): C. F. Evans and L. P. Shriver
Affiliation:
Keywords: Multiple Sclerosis, demyelinating disease, Demyelination, Autoimmune, Glatiramer Acetate, Immunomodulators, Mitoxantrone, Gene Therapy, Microarrays, BIOMARKERS
Abstract: Multiple sclerosis (MS) is a demyelinating disease of the central nervous system of unknown etiology. Two of the major therapies for the treatment of MS, interferon-β and glatiramer acetate, show only limited evidence that long-term treatment slows disability. There is a great need for new drugs that will halt, reverse, and prevent the development of MS. This article reviews therapies currently in use and describes innovative strategies being developed to alter the disease course. New technologies in gene expression profiling offer hopeful directions toward the design of successful drug therapies and diagnostic testing for MS. Additionally, the new fields of genomics and proteomics offer the promise of novel treatments, and should help to reveal the mechanisms of disease initiation and pathological progression.
Export Options
About this article
Cite this article as:
Evans F. C. and Shriver P. L., Multiple Sclerosis: Emerging Opportunities for Therapeutic Intervention, Current Drug Targets - CNS & Neurological Disorders 2002; 1 (1) . https://dx.doi.org/10.2174/1568007023339526
DOI https://dx.doi.org/10.2174/1568007023339526 |
Print ISSN 1568-007X |
Publisher Name Bentham Science Publisher |
Online ISSN 1568-007X |
Related Articles
-
Animal Models of Central Nervous System Immune-Mediated Diseases: Therapeutic Interventions with Bioactive Peptides and Mimetics
Current Medicinal Chemistry Drug Discovery and Protein Tyrosine Phosphatases
Current Medicinal Chemistry Anti-Angiogenic Drugs and Biomarkers in Non-Small-Cell Lung Cancer: 'A Hard Days Night'
Current Pharmaceutical Design Antioxidant Food Supplements and Obesity-Related Inflammation
Current Medicinal Chemistry Regulation of Energy Balance by Peptides: A Review
Current Protein & Peptide Science Wnt Signaling in Inflammation in Tissue Repair and Regeneration
Current Protein & Peptide Science Immune Receptors, Cadherins and their Interactions
Current Immunology Reviews (Discontinued) The Use of Leukotriene Modifying Drugs in Asthma and Other Respiratory Diseases
Current Drug Targets - Inflammation & Allergy Potent Chemopreventive Agents Against Pancreatic Cancer
Current Cancer Drug Targets Is Tretinoin Still a Key Agent for Photoaging Management?
Mini-Reviews in Medicinal Chemistry Mechanisms of Tumor Cell Necrosis
Current Pharmaceutical Design Transition Metals for Conjugation of Polyunsaturated Acids and their Esters
Current Organic Chemistry Viral Latent Proteins as Targets for Kaposis Sarcoma and Kaposis Sarcoma-associated Herpesvirus (KSHV / HHV-8) Induced Lymphoma
Current Drug Targets - Infectious Disorders Drug Target in Eosinophilic Meningitis Caused by Angiostrongylus cantonensis
Infectious Disorders - Drug Targets Recent Patents and New Strategies in the Treatment of Psoriasis
Recent Patents on Anti-Infective Drug Discovery Recent Patents Reveal Microtubules as Persistent Promising Target for Novel Drug Development for Cancers
Recent Patents on Anti-Infective Drug Discovery The Chick Embryo Chorioallantoic Membrane as a Model for in vivo Research on Anti-Angiogenesis
Current Pharmaceutical Biotechnology Red Blood Cell-Encapsulated L-Asparaginase: Potential Therapy of Patients with Asparagine Synthetase Deficient Acute Myeloid Leukemia
Protein & Peptide Letters Transcription Factor Profiling Shows New Ways Towards New Treatment Options of Cutaneous T cell lymphomas
Current Drug Discovery Technologies Etoposide, Topoisomerase II and Cancer
Current Medicinal Chemistry - Anti-Cancer Agents